The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Post-hoc analysis evaluating selinexor maintenance therapy in patients with TP53wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.
 
Jalid Sehouli
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Clovis Oncology; Corcept Therapeutics; Daiichi; Eisai; Esteve Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Hexal; Incyte; Jenapharm; Johnson & Johnson; Kyowa Kirin International; Medtronic Covidien; MSD Oncology; Myriad Pharmaceuticals; Novartis; Oncoinvent; Pfizer; PharmaMar; Phytolife Nutrition; Roche; Vifor Pharma
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer/Vital; Bristol Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Eisai; GlaxoSmithKline; Immunogen; Ingress Health; Intuitive Surgical; Johnson & Johnson; Karyopharm Therapeutics; Lilly; Merck; MSD Oncology; Mundipharma; Novocure; Oncoinvent; Pfizer; PharmaMar; Roche; Sanofi Aventis GmbH; Seagen; Sobi; Tubulis GmbH
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); IQvia (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); MSD Oncology (Inst); Mural (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG
 
Ignace Vergote
Consulting or Advisory Role - Agenus; Akeso Biopharma; AstraZeneca; Bristol Myers Squibb; Corcept Therapeutics; Daiichi Sankyo Europe GmbH; Eisai; Genmab; GlaxoSmithKline; Immunogen; ITM Isotope Technologies Munich; Karyopharm Therapeutics; Kronos bio; Mersana; MSD; Novocure; Oncoinvent; OncXerna Therapeutics; Regeneron; Roche; Sanofi; Seagen; Verastem; Zentalis
 
Erika Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); Arvinas (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Johnson and Johnson (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Jose Perez-Fidalgo
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Deciphera; Eisai; GlaxoSmithKline; Karyopharm Therapeutics; MSD; Pharmaand; Regeneron
Speakers' Bureau - AstraZeneca Spain; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology; PharmaMar; Seagen
Research Funding - AstraZeneca Spain (Inst); GlaxoSmithKline (Inst); Pharmamar (Inst)
Patents, Royalties, Other Intellectual Property - Pending patent
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca Spain; Novartis
 
Giorgio Valabrega
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD
Consulting or Advisory Role - Eisai; GlaxoSmithKline
Travel, Accommodations, Expenses - MSD
 
Toon Van Gorp
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Speakers' Bureau - Abbvie (Inst); AstraZeneca (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Klaudia Reginacova
No Relationships to Disclose
 
Ora Rosengarten
No Relationships to Disclose
 
Lucy Gilbert
Honoraria - GlaxoSmithKline; Merck; Repare Therapeutics
Consulting or Advisory Role - Corcept Therapeutics; Eisai; GlaxoSmithKline; Immunogen; Kora Healthcare; Merck
Research Funding - Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Esperas Pharma (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Immunogen (Inst); IMV (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Repare Therapeutics (Inst); Roche (Inst); Seagen (Inst); Shattuck Labs (Inst); Sutro BioPharma Inc (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Corcept Therapeutics; Eisai; EndomEra; GlaxoSmithKline; GOG Foundation; Merck; Zentalis
 
Iwona Podzielinski
No Relationships to Disclose
 
Eva Guerra
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; GlaxoSmithKline/Tesaro; Pharma&; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; GlaxoSmithKline/Tesaro; PharmaMar; Roche
Expert Testimony - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; PharmaMar; Roche
Travel, Accommodations, Expenses - GlaxoSmithKline/Tesaro; Roche
 
Alice Bergamini
Speakers' Bureau - MSD/AZ, GSK
 
Isabelle Cadron
No Relationships to Disclose
 
Dirk Bauerschlag
Honoraria - MSD, Abbvie, AstaZeneca
Consulting or Advisory Role - MSD, Abbvie, AstraZeneca
 
Michael Teneriello
No Relationships to Disclose
 
Jerónimo Martínez-García
Consulting or Advisory Role - AstraZeneca Spain; GlaxoSmithKline
Travel, Accommodations, Expenses - MSD Oncology; PharmaMar; Roche
 
Alfred Guirguis
No Relationships to Disclose
 
Pratheek Kalyanapu
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Mansoor Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; ESMO Congress; Merck
Other Relationship - IBM